1
|
van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol 2014; 10:102-14. [PMID: 24322649 DOI: 10.1038/nrendo.2013.246] [Citation(s) in RCA: 106] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
In patients with neuroendocrine tumours (NETs), a combination of morphological imaging and nuclear medicine techniques is mandatory for primary tumour visualization, staging and evaluation of somatostatin receptor status. CT and MRI are well-suited for discerning small lesions that might escape detection by single photon emission tomography (SPECT) or PET, as well as for assessing the local invasiveness of the tumour or the response to therapy. Somatostatin receptor imaging, by (111)In-pentetreotide scintigraphy or PET with (68)Ga-labelled somatostatin analogues, frequently identifies additional lesions that are not visible on CT or MRI scans. Currently, somatostatin receptor scintigraphy with (111)In-pentetreotide is the more frequently available of the two techniques to determine somatostatin receptor expression and is needed to select patients for peptide receptor radionuclide therapy. In the future, because of its higher sensitivity, PET with (68)Ga-labelled somatostatin analogues is expected to replace somatostatin receptor scintigraphy. Whereas (18)F-FDG-PET is only used in high-grade neuroendocrine cancers, PET-CT with (18)F-dihydroxy-L-phenylalanine or (11)C-5-hydroxy-L-tryptophan is a useful problem-solving tool and could be considered for the evaluation of therapy response in the future. This article reviews the role of imaging for the diagnosis and management of intestinal and pancreatic NETs. Response evaluation and controversies in NET imaging will also be discussed.
Collapse
Affiliation(s)
- Martijn van Essen
- Department of Nuclear Medicine, Erasmus MC, 's Gravendijkwal 230, Rotterdam, 3015 GD, Netherlands
| | - Anders Sundin
- Department of Radiology, Karolinska University Hospital, Stockholm, 17176 Stockholm, Sweden
| | - Eric P Krenning
- Department of Nuclear Medicine, Erasmus MC, 's Gravendijkwal 230, Rotterdam, 3015 GD, Netherlands
| | - Dik J Kwekkeboom
- Department of Nuclear Medicine, Erasmus MC, 's Gravendijkwal 230, Rotterdam, 3015 GD, Netherlands
| |
Collapse
|
2
|
Kim SH, Lee JM, Han JK, Lee JY, Kim KW, Cho KC, Choi BI. Intrapancreatic accessory spleen: findings on MR Imaging, CT, US and scintigraphy, and the pathologic analysis. Korean J Radiol 2008; 9:162-74. [PMID: 18385564 PMCID: PMC2627219 DOI: 10.3348/kjr.2008.9.2.162] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Although the tail of the pancreas is the second most common site of an accessory spleen, intrapancreatic accessory spleen (IPAS) has rarely been noted radiologically. However, as the imaging techniques have recently advanced, IPAS will be more frequently detected as an incidental pancreatic nodule on CT or MRI. Because accessory spleens usually pose no clinical problems, it is important to characterize accessory spleens as noninvasively as possible. An IPAS has similar characteristics to those of the spleen on the precontrast and contrast-enhanced images of all the imaging modalities. In particular, inhomogeneous enhancement of an IPAS in its early phases may be a diagnostic clue. Superparamagnetic iron oxide (SPIO)-enhanced MRI and Levovist-enhanced US, and the mechanisms of which are theoretically similar to that of Tc-99m scintigraphy, can be used as alternative tools to confirm the diagnosis of IPAS. An IPAS shows a significant signal drop similar to the spleen on the SPIO-enhanced T2 or T2*-weighted imaging and prolonged enhancement on the delayed hepatosplenic phase of contrast-enhanced US. We review and illustrate the differential points between IPAS and hypervascular pancreatic tumors in this manuscript.
Collapse
Affiliation(s)
- Se Hyung Kim
- Department of Radiology, Seoul National University Hospital, Seoul, Korea
| | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
MR imaging is a valuable tool in the assessment of the full spectrum of pancreatic diseases. MR imaging techniques are sensitive for the evaluation of pancreatic disorders in the following settings: (1) TI-weighted fat-suppressed and dynamic gadolinium-enhanced SGE imaging for the detection of chronic pancreatitis, ductal adeno-carcinoma, and islet-cell tumors; (2) T2-weighted fat-suppressed imaging and T2-weighted breath-hold imaging for the detection of islet-cell tumors;and (3) precontrast breath-hold SGE imaging for the detection of acute pancreatitis. Relatively specific morphologic and signal intensity features permit characterization of acute pancreatitis,chronic pancreatitis, ductal adenocarcinoma, insulinoma, gastrinoma, glucagonoma, microcystic cystadenoma, macrocystic cystadenoma, and solid and papillary epithelial neoplasm. MR imaging is effective as a problem-solving modality because it distinguishes chronic pancreatitis from normal pancreas and chronic pancreatitis with focal enlargement from pancreatic cancer in the majority of cases.MR imaging studies should be considered in the following settings: (1) in patients with elevated serum creatinine, allergy to iodine contrast, or other contraindications for iodine contrast administration; (2) in patients with prior CT imaging who have focal enlargement of the pancreas with no definable mass; (3) in patients in whom clinical history is worrisome for malignancy and in whom findings on CT imaging are equivocal or difficult to interpret; and (4) in situations requiring distinction between chronic pancreatitis with focal enlargement and pancreatic cancer. Patients with biochemical evidence of islet-cell tumors should be examined by MR imaging as the first-line imaging modality because of the high sensitivity of MR imaging for detecting the presence of islet-cell tumors and determining the presence of metastatic disease.
Collapse
Affiliation(s)
- Ertan Pamuklar
- Department of Radiology, University of North Carolina, 101 Manning Drive, CB #7510, Chapel Hill, NC 27599-7510, USA
| | | |
Collapse
|
4
|
Abstract
Islet cells tumours are a range of rare neoplasms of neuroendocrine origin arising in or close to the pancreas. The normal islet cells of Langerhans in the pancreas contain B-cells (which secrete insulin), A-cells (which secrete glucagon), D-cells (which secrete somatostatin), D1-cells (which secrete pancreatic polypeptide) and D2-cells (which secrete vasoactive intestinal peptide). The majority (85%) of islet cell tumours secrete one or more of these hormones, or other substances not normally found in the adult pancreas (although often present in the foetal pancreas), notably gastrin.
Collapse
Affiliation(s)
- R Reznek
- Academic Department of Diagnostic Radiology St Bartholomew's Hospital, London, UK.
| |
Collapse
|
5
|
|
6
|
Gotwald TF, Zinreich SJ, Schocke M, Frede T, Bellmann R, Zur Nedden D. CT and MR imaging of orbital metastasis from islet cell carcinoma of the pancreas. AJR Am J Roentgenol 2000; 175:475-6. [PMID: 10915697 DOI: 10.2214/ajr.175.2.1750475] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- T F Gotwald
- Department of Radiology, Neuroradiology Division, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
| | | | | | | | | | | |
Collapse
|
7
|
Abstract
Pancreatic endocrine tumors arise from the amine precursor uptake and decarboxylation (APUD) cells of the pancreas and behave in a different fashion both biologically and clinically from pancreatic adenocarcinoma. Gastrinomas and insulinomas are the two most common pancreatic endocrine tumors. Unlike pancreatic adenocarcinoma, in which tumor stage, resectability, and prognosis are determined by the tumor, nodes, and metastasis (TNM) classification, the prognosis of pancreatic endocrine tumors is determined by the presence of liver but not regional lymph node metastasis. This review focuses predominantly on the different diagnostic tools available to the clinician and the relative merits of each modality. The sensitivities of computed tomography, magnetic resonance imaging, somatostatin receptor scintigraphy, endoscopic ultrasound, and angiography with venous sampling for diagnosing islet cell tumors are compared. A diagnostic algorithm for the management of these tumors is provided at the end of the discussion.
Collapse
Affiliation(s)
- L Somogyi
- Division of Digestive Diseases, University of Cincinnati, 231 Bethesda Avenue, Cincinnati, OH 45267-0595, USA.
| | | |
Collapse
|
8
|
Abstract
We reviewed our 8.5 year experience with magnetic resonance imaging (MRI) in the demonstration of neuroendocrine tumors of the pancreas using precontrast fat-suppressed T1-weighted, fat-suppressed T2-weighted, and serial post-gadolinium T1-weighted images, to describe the spectrum of appearances of these tumors. All MR examinations of patients with histologically proven neuroendocrine tumors were retrospectively reviewed. Histological type, tumor location, tumor diameter, signal intensity on precontrast images, enhancement patterns, and presence and appearance of metastases were determined. Twenty-two patients had histologically proved neuroendocrine tumors detected by MRI over the 8.5 year period. Histological types were gastrinoma (n = 8), insulinoma (n = 3), glucagonoma (n = 2), somatostatinoma (n = 1), VIPoma (n = 1), ACTHoma (n = 1), carcinoid (n = 1), and five untyped tumors. Primary tumors ranged in diameter from 1 to 6.2 cm. There was one histopathology-proven false-positive neuroendocrine tumor. The positive predictive value for MRI in the detection of these tumors was 96%. The most common appearance on precontrast images was low signal intensity on T1-weighted images and high signal intensity on T2-weighted images, which was observed in tumors in 18 of 22 patients. Moderate or intense early enhancement of all or portions of the primary tumors was observed in tumors in 19 of 22 patients either as uniform homogeneous, ring, or diffuse heterogeneous enhancement. Enhancement was minimal on these images in the other three patients. Gastrinomas enhanced in a ring pattern in 7 of 8 patients whereas the majority (9 of 11 patients) of noninsulinoma-nongastrinoma and untyped tumors enhanced in a diffuse heterogeneous fashion. Liver metastases were present in 13/22 patients including 3/8 with gastrinoma and 9/11 with noninsulinoma-nongastrinoma tumors. Most neuroendocrine tumors of the pancreas are low signal intensity on fat-suppressed T1-weighted images and moderately high in signal intensity on fat-suppressed T2-weighted images, although variations do exist. Tumors most often enhance in an early moderately intense fashion. Gastrinomas are often different in appearance than other neuroendocrine tumors in that they usually enhance in a ring fashion whereas nongastrinoma-noninsulinoma tumors usually enhance in a heterogeneous fashion.
Collapse
Affiliation(s)
- R C Semelka
- Department of Radiology, University of North Carolina, Chapel Hill 27599, USA
| | | | | | | |
Collapse
|
9
|
Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000; 214:483-90. [PMID: 10671597 DOI: 10.1148/radiology.214.2.r00fe32483] [Citation(s) in RCA: 183] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
PURPOSE To determine the sensitivity and specificity of magnetic resonance (MR) imaging for depicting pancreatic small, functional islet cell tumors and the minimum number of sequences for expedient diagnosis. MATERIALS AND METHODS Twenty-eight patients clinically suspected to have functional islet cell tumors underwent T1- and T2-weighted spin-echo (SE) MR imaging with and without fat suppression, T2-weighted fast SE imaging, and spoiled gradient-echo (GRE) imaging before and after injection of gadopentetate dimeglumine. Sensitivity, specificity, and the best and minimum number of sequences for definitive diagnosis were determined. RESULTS MR images depicted proved islet cell tumors in 17 of 20 patients (sensitivity, 85%). Images were true-negative in eight patients with negative follow-up examination results for more than 1 year. Specificity was 100%; positive predictive value, 100%; and negative predictive value, 73%. Among 20 patients with tumor, T1-weighted SE images with fat suppression and nonenhanced spoiled GRE images each showed lesions in 15 (75%); T2-weighted conventional SE with fat suppression, in 13 (65%); gadolinium-enhanced spoiled GRE, in 12 (60%); and T2-weighted fast SE, in seven of 10 patients (70%). CONCLUSION MR imaging accurately depicts small islet cell tumors. T2-weighted fast SE and spoiled GRE sequences usually suffice. Gadolinium-enhanced sequences are needed only if MR imaging results are equivocal or negative.
Collapse
Affiliation(s)
- R F Thoeni
- Department of Radiology, University of California San Francisco School of Medicine, PO Box 0628, San Francisco, CA 94143-0628, USA
| | | | | | | | | |
Collapse
|
10
|
Vandevenne JE, Deckers F, Mana F, Küçükaycan M, d'Archambeau O, De Schepper AM. Insulinoma associated with liver lesions: value of MR imaging. Am J Gastroenterol 1998; 93:1559-62. [PMID: 9732946 DOI: 10.1111/j.1572-0241.1998.00483.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We report on a middle-aged woman who presented with clinical and biochemical findings of insulinoma. Preoperative evaluation by ultrasound, CT, and angiography located the pancreatic lesion but also revealed two focal liver lesions. The latter were interpreted as metastases. MR imaging with injection of superparamagnetic iron oxide particles not only localized the insulinoma but proved to be the only noninvasive technique capable to exclude presence of liver metastases preoperatively. This reversed management to minimal laparoscopic surgery. Recent literature of preoperative imaging evaluation of insulinoma and focal liver lesions is discussed.
Collapse
Affiliation(s)
- J E Vandevenne
- Department of Radiology, Universitair Ziekenhuis Antwerpen, University of Antwerp, Belgium
| | | | | | | | | | | |
Collapse
|
11
|
|
12
|
|
13
|
Soyer P, Tidjani K, Laissy JP, Sibert A, Menu Y. Dynamic Gd-DOTA-enhanced MR imaging of hepatic metastases from pancreatic neuroendocrine tumors. Eur J Radiol 1994; 18:180-4. [PMID: 7957287 DOI: 10.1016/0720-048x(94)90331-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The aim of this study was to determine the MR imaging features of hepatic metastases from pancreatic neuroendocrine tumors (HMPNT), and to assess their enhancement characteristics on dynamic gadolinium-chelate-enhanced MR imaging. Twelve consecutive patients with pathologically proven HMPNT underwent spin-echo (SE) and dynamic gradient-recalled echo (GRE) MR imaging before and after intravenous administration of a gadolinium-chelate (gadolinium tetraazacyclododecanetetraacetic acid; Gd-DOTA). MR examinations were performed prospectively and interpreted retrospectively in consensus by two radiologists. Fifty-five HMPNT were identified in matching anatomic sections on the different MR sequences and included in the study. On T1-weighted SE images, 45 HMPNT (82%) were hypointense and 10 HMPNT (18%) were isointense. On T2-weighted SE images 55 HMPNT (100%) were hyperintense. On GRE images obtained 20 s after Gd-DOTA injection, 41 HMPNT (75%) showed slight peripheral enhancement, and 14 HMPNT (25%) showed internal enhancement. Forty-four HMPNT (80%) were heterogeneous. On GRE images obtained 4 min after Gd-DOTA injection, 37 HMPNT (67%) showed peripheral enhancement, and 18 HMPNT (33%) showed a global and almost complete enhancement. Heterogeneity of enhancement was seen in all 55 HMPNT (100%). Although HMPNT exhibit a large spectrum of MR features, early enhancement and heterogeneity on dynamic GRE MR images are suggestive features of HMPNT.
Collapse
Affiliation(s)
- P Soyer
- Department of Radiology, Hôpital Foch, Suresnes, France
| | | | | | | | | |
Collapse
|